Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bemarituzumab + CAPOX + nivolumab
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a **combination regimen** consisting of three agents used or investigated primarily for the first-line treatment of **locally advanced or metastatic gastric and gastroesophageal junction cancer with FGFR2b overexpression**. - **Bemarituzumab** is a humanized, afucosylated monoclonal antibody that selectively binds to and inhibits signaling through **fibroblast growth factor receptor 2b (FGFR2b)**, leading to impaired tumor growth and enhanced antibody-dependent cellular cytotoxicity (ADCC)[1][3][5]. - **CAPOX** refers to the combination of **capecitabine** (an oral prodrug of 5-fluorouracil, a DNA synthesis inhibitor) and **oxaliplatin** (a platinum-based DNA crosslinker), forming a standard chemotherapy backbone for GI cancers. - **Nivolumab** is a monoclonal antibody that targets **programmed cell death protein 1 (PD-1)**, functioning as an **immune checkpoint inhibitor** to enhance anti-tumor T-cell responses. This combination regimens leverages: - Targeted inhibition of tumor growth signals (bemarituzumab/FGFR2b), - Broad cytotoxic chemotherapy (CAPOX), - Immune system activation against cancer cells (nivolumab/PD-1 antagonism).
- Other names
- bemarituzumab + CAPOX + nivolumab
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)FGFR2b (Fibroblast growth factor receptor 2 IIIb isoform)TS (Thymidylate synthase)
Beyond the preview
Go deeper on bemarituzumab + CAPOX + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bemarituzumab + CAPOX + nivolumab.